Literature DB >> 6213292

Immunobiology of primary intracranial tumors. VI. Suppressor cell function and lectin-binding lymphocyte subpopulations in patients with cerebral tumors.

T L Roszman, W H Brooks, L H Elliott.   

Abstract

Peripheral blood lymphocytes obtained from patients with primary intracranial tumors were assessed for the presence of Concanavalin-A-activated, glass-adherent, and spontaneous, nonspecific suppressor cells. Additionally, the effect of indomethacin on phytohemagglutinin (PHA)-induced blastogenesis was determined. No significant differences in cellular suppressor mechanisms in these patients and normal controls were observed. However, shifts in lymphocyte populations were demonstrable when cells were separated according to quantification of PHA-L surface binding sites by flow microfluorometry. Therefore, although impaired cellular responsiveness in patients with cerebral neoplasms does not appear to be due to alterations in suppressor-cell function, changes in lymphocyte subpopulations occur that may be induced as an immunobiological consequence of primary central nervous system neoplasia and contribute to suppressed host immunocompetence.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6213292     DOI: 10.1002/1097-0142(19821001)50:7<1273::aid-cncr2820500709>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  Immunobiology of brain tumors.

Authors:  E Frank; N de Tribolet
Journal:  Neurosurg Rev       Date:  1986       Impact factor: 3.042

Review 2.  The immunobiology of human gliomas.

Authors:  V Piguet; A C Diserens; S Carrel; J P Mach; N de Tribolet
Journal:  Springer Semin Immunopathol       Date:  1985

Review 3.  Immunology of gliomas.

Authors:  N de Tribolet
Journal:  Childs Nerv Syst       Date:  1989-04       Impact factor: 1.475

4.  Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors.

Authors:  L H Elliott; W H Brooks; T L Roszman
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

5.  Relation between the site of primary intracranial tumors and mitogenic responses of blood lymphocytes.

Authors:  H Blomgren; U Blom; H Ulén
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 6.  Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Authors:  John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Darell D Bigner
Journal:  Semin Immunol       Date:  2008-06-09       Impact factor: 11.130

Review 7.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

Review 8.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

9.  Cell-mediated cytotoxicity in glioma-bearing patients: differential responses of peripheral blood mononuclear cells to stimulation with interleukin-2 and microbial antigen.

Authors:  C Ausiello; A Maleci; G C Spagnoli; G Antonelli; A Cassone
Journal:  J Neurooncol       Date:  1988-12       Impact factor: 4.130

10.  Immunological studies in patients with central nervous system tumors.

Authors:  L Palma; V Moschese; E Galli; C Barbieri; V R Lombardi; P Rossi
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.